Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 24 | -1.72 Decreased by -356.72% | -1.65 Decreased by -4.24% |
| Nov 2, 23 | -1.64 Decreased by -10.07% | -1.7 Increased by +3.53% |
| Aug 3, 23 | -1.51 Increased by +10.12% | -1.56 Increased by +3.21% |
| May 4, 23 | -1.47 Increased by +15.52% | -1.7 Increased by +13.53% |
| Feb 23, 23 | 0.67 Increased by +138.51% | -1.62 Increased by +141.36% |
| Nov 3, 22 | -1.49 Increased by +4.49% | -1.76 Increased by +15.34% |
| Aug 4, 22 | -1.68 Decreased by -16.67% | -1.75 Increased by +4% |
| May 5, 22 | -1.74 Decreased by -106.46% | -1.81 Increased by +3.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 7.1 M Increased by +64.8% | -95.94 M Decreased by -155.71% | Decreased by -1.35 K% Decreased by -133.8% |
| Sep 30, 23 | 7.4 M Increased by +110.44% | -91.32 M Decreased by -26.13% | Decreased by -1.23 K% Increased by +40.06% |
| Jun 30, 23 | 6.71 M Increased by +20.24% | -83.81 M Increased by +2.52% | Decreased by -1.25 K% Increased by +18.93% |
| Mar 31, 23 | 5.61 M Increased by +574.16% | -71.42 M Increased by +19.21% | Decreased by -1.27 K% Increased by +88.02% |
| Dec 31, 22 | 4.31 M Increased by +10.41 M% | 172.22 M Increased by +282% | Increased by +4 K% Increased by +100% |
| Sep 30, 22 | 3.52 M Increased by +N/A% | -72.4 M Increased by +18.43% | Decreased by -2.06 K% Decreased by N/A% |
| Jun 30, 22 | 5.58 M Decreased by -85.05% | -85.97 M Increased by +0.28% | Decreased by -1.54 K% Decreased by -567.16% |
| Mar 31, 22 | 832 K Decreased by -97.99% | -88.4 M Decreased by -104.72% | Decreased by -10.63 K% Decreased by -334.74% |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.